Immix Biopharma, Inc. (IMMX) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held on June 20, 2025. Immix Biopharma, Inc., a Delaware corporation and emerging growth company, is headquartered in Los Angeles, California. The filing details the voting outcomes for director elections and the ratification of the independent auditor.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial performance data. There is no information provided regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Voting Results
Stockholders representing 20,092,566 shares (72.1% of voting shares) were present, constituting a quorum. The following matters were approved:
- Proposal 1: Election of Directors
- All eight nominees were elected to serve until the next annual meeting.
- High Support: Ilya Rachman, Jason Hsu, Magda Marquet, and Yekaterina Chudnovsky received over 97% "For" votes.
- Lower Support: Helen C. Adams, Carey Ng, and Jane Buchan received approximately 91-92% "For" votes, with higher "Withheld" counts compared to other nominees.
- Broker Non-Votes: Approximately 5.49 million shares were recorded as broker non-votes for all director proposals.
- Proposal 2: Ratification of Auditor
- Crowe LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2025.
- Voting Breakdown: 19,946,506 For; 47,622 Against; 98,438 Abstentions.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports the administrative results of the annual meeting.
Investor Verification Checklist
- Verify the specific reasons for the higher "Withheld" votes for directors Helen C. Adams, Carey Ng, and Jane Buchan by reviewing the full Proxy Statement.
- Confirm the total number of outstanding shares as of the record date (April 22, 2025) to contextualize the 72.1% participation rate.
- Review the upcoming 10-K or 10-Q filings for the actual financial performance data, as this 8-K does not include it.
- Check for any subsequent filings regarding the transition of the independent auditor to Crowe LLP.